Methylphenidate for apathy and functional status in Dementia of the alzheimer type

Prasad R. Padala, William J. Burke, Valerie K. Shostrom, Subhash Bhatia, Steven P. Wengel, Jane F. Potter, Frederick Petty

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

OBJECTIVE: Apathy is the most common behavioral problem in persons with dementia of the Alzheimer type (DAT). Treatment of apathy in DAT is not systematically studied. The purpose of this study was to evaluate the response of apathy to methylphenidate treatment and to examine whether functional status improved. METHODS: The authors conducted a 12-week open-labeled study with immediate release formulation of methylphenidate. Twenty-three patients with DAT scoring >40 on the Apathy Evaluation Scale (AES) were recruited. Repeated measures analysis of variance and correlation analysis were performed. RESULTS: None of the patients dropped out of the study because of adverse events. Significant improvement in apathy was noted during 12 weeks. Significant improvement was also noted in depression, Mini-Mental State Examination score, and functional status. There was no correlation between changes in the AES and depression scores. CONCLUSIONS: Methylphenidate was well tolerated in these patients with DAT. Apathy improved with the use of methylphenidate.

Original languageEnglish (US)
Pages (from-to)371-374
Number of pages4
JournalAmerican Journal of Geriatric Psychiatry
Volume18
Issue number4
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Apathy
Methylphenidate
Alzheimer Disease
Analysis of Variance
Depression
Therapeutics

All Science Journal Classification (ASJC) codes

  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Methylphenidate for apathy and functional status in Dementia of the alzheimer type. / Padala, Prasad R.; Burke, William J.; Shostrom, Valerie K.; Bhatia, Subhash; Wengel, Steven P.; Potter, Jane F.; Petty, Frederick.

In: American Journal of Geriatric Psychiatry, Vol. 18, No. 4, 01.01.2010, p. 371-374.

Research output: Contribution to journalArticle

Padala, Prasad R. ; Burke, William J. ; Shostrom, Valerie K. ; Bhatia, Subhash ; Wengel, Steven P. ; Potter, Jane F. ; Petty, Frederick. / Methylphenidate for apathy and functional status in Dementia of the alzheimer type. In: American Journal of Geriatric Psychiatry. 2010 ; Vol. 18, No. 4. pp. 371-374.
@article{bcd7414da4f944e5939d2c2018a97f62,
title = "Methylphenidate for apathy and functional status in Dementia of the alzheimer type",
abstract = "OBJECTIVE: Apathy is the most common behavioral problem in persons with dementia of the Alzheimer type (DAT). Treatment of apathy in DAT is not systematically studied. The purpose of this study was to evaluate the response of apathy to methylphenidate treatment and to examine whether functional status improved. METHODS: The authors conducted a 12-week open-labeled study with immediate release formulation of methylphenidate. Twenty-three patients with DAT scoring >40 on the Apathy Evaluation Scale (AES) were recruited. Repeated measures analysis of variance and correlation analysis were performed. RESULTS: None of the patients dropped out of the study because of adverse events. Significant improvement in apathy was noted during 12 weeks. Significant improvement was also noted in depression, Mini-Mental State Examination score, and functional status. There was no correlation between changes in the AES and depression scores. CONCLUSIONS: Methylphenidate was well tolerated in these patients with DAT. Apathy improved with the use of methylphenidate.",
author = "Padala, {Prasad R.} and Burke, {William J.} and Shostrom, {Valerie K.} and Subhash Bhatia and Wengel, {Steven P.} and Potter, {Jane F.} and Frederick Petty",
year = "2010",
month = "1",
day = "1",
doi = "10.1097/JGP.0b013e3181cabcf6",
language = "English (US)",
volume = "18",
pages = "371--374",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Methylphenidate for apathy and functional status in Dementia of the alzheimer type

AU - Padala, Prasad R.

AU - Burke, William J.

AU - Shostrom, Valerie K.

AU - Bhatia, Subhash

AU - Wengel, Steven P.

AU - Potter, Jane F.

AU - Petty, Frederick

PY - 2010/1/1

Y1 - 2010/1/1

N2 - OBJECTIVE: Apathy is the most common behavioral problem in persons with dementia of the Alzheimer type (DAT). Treatment of apathy in DAT is not systematically studied. The purpose of this study was to evaluate the response of apathy to methylphenidate treatment and to examine whether functional status improved. METHODS: The authors conducted a 12-week open-labeled study with immediate release formulation of methylphenidate. Twenty-three patients with DAT scoring >40 on the Apathy Evaluation Scale (AES) were recruited. Repeated measures analysis of variance and correlation analysis were performed. RESULTS: None of the patients dropped out of the study because of adverse events. Significant improvement in apathy was noted during 12 weeks. Significant improvement was also noted in depression, Mini-Mental State Examination score, and functional status. There was no correlation between changes in the AES and depression scores. CONCLUSIONS: Methylphenidate was well tolerated in these patients with DAT. Apathy improved with the use of methylphenidate.

AB - OBJECTIVE: Apathy is the most common behavioral problem in persons with dementia of the Alzheimer type (DAT). Treatment of apathy in DAT is not systematically studied. The purpose of this study was to evaluate the response of apathy to methylphenidate treatment and to examine whether functional status improved. METHODS: The authors conducted a 12-week open-labeled study with immediate release formulation of methylphenidate. Twenty-three patients with DAT scoring >40 on the Apathy Evaluation Scale (AES) were recruited. Repeated measures analysis of variance and correlation analysis were performed. RESULTS: None of the patients dropped out of the study because of adverse events. Significant improvement in apathy was noted during 12 weeks. Significant improvement was also noted in depression, Mini-Mental State Examination score, and functional status. There was no correlation between changes in the AES and depression scores. CONCLUSIONS: Methylphenidate was well tolerated in these patients with DAT. Apathy improved with the use of methylphenidate.

UR - http://www.scopus.com/inward/record.url?scp=77949502907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949502907&partnerID=8YFLogxK

U2 - 10.1097/JGP.0b013e3181cabcf6

DO - 10.1097/JGP.0b013e3181cabcf6

M3 - Article

VL - 18

SP - 371

EP - 374

JO - American Journal of Geriatric Psychiatry

JF - American Journal of Geriatric Psychiatry

SN - 1064-7481

IS - 4

ER -